Under several pathological conditions, reactive oxygen species-induced damages play important roles in pathogenesis (1-3). High levels of reactive oxygen species are generated from a variety of sources such as the xanthine oxidase system (1), the leakage of electrons from the mitochondrial respiratory chain (2, 4), the cyclooxygenase pathway of arachidonic acid metabolism (3,5), and the respiratory burst of phagocyte cells (6, 7), and they can cause DNA damage-generating singlestranded DNA breaks (8). Poly(ADP-ribose)polymerase (PARP-1, 2 EC 2.4.2.30) is a multifunctional nuclear enzyme (9) that is activated by DNA strand breaks and catalyzes the covalent coupling of branched chains of ADP-ribose units to various nuclear proteins such as histone proteins and PARP-1 itself. PARP-1 is involved in chromatin remodeling, DNA repair, replication, transcription, and the maintenance of genomic stability by, in part, poly(ADP-ribosyl)ation (9). With moderate amounts of DNA damage, PARP-1 is thought to participate in the DNA repair process (10, 11). However, oxidative stress, which induces a large amount of DNA damage, can cause excessive activation of PARP-1, leading to depletion of its substrate NAD ϩ ; and in an effort to resynthesize NAD ϩ , ATP is also depleted, resulting in cell death as a consequence of energy loss (12-15). PARP inhibitors show pronounced protection against myocardial ischemia (16), neuronal ischemia (17, 18), acute lung inflammation (19), acute septic shock (20), zymogen-induced multiple organ failure (21), and diabetic pancreatic damage (22-24), providing evidence for the role of excessive PARP-1 activation in cell death. It is believed that by preventing excessive NAD ϩ and ATP utilization, PARP inhibitors protect cells against oxidative damage, but some recent data suggest a more complex mechanism for the cytoprotection (25, 26). There is evidence that PARP activation can contribute to exaggeration of mitochondrial damage (27) and mitochondrial reactive oxygen species production (28), indicating that PARP activation can modulate processes outside of the nucleus. Recent works reported the existence of mitochondrial PARP that can be blocked with PARP-1 inhibitors (29); therefore, it would be important to clarify whether the mitochondrial protection by PARP inhibitors is a direct consequence of the inhibition of mitochondrial ADP-ribosylation or the inhibition of nuclear PARP modulation by yet unidentified processes that are responsible for the mitochondrial protection. Our previous works demonstrated that PARP inhibitors induced the phosphorylation and activation of Akt in the liver, lung, and spleen of lipopolysaccharide-treated mice, raising the possibility that the protective effect of PARP inhibition can be mediated through the PI3-kinase/Akt pathway (30). These observations indicate that the protective effect of PARP inhibitors should be far more In the present study, we analyzed the effect of PARP inhibition by pharmacologic agents, by the transdominant expression of the PARP N-terminal DNA...
BackgroundRed wine polyphenols can prevent cardiovascular and inflammatory diseases. Resveratrol, the most extensively studied constituent, is unlikely to solely account for these beneficial effects because of its rather low abundance and bioavailability. Malvidin is far the most abundant polyphenol in red wine; however, very limited data are available about its effect on inflammatory processes and kinase signaling pathways.Methods & FindingsThe present study was carried out by using RAW 264.7 macrophages stimulated by bacterial lipopolysaccharide in the presence and absence of malvidin. From the cells, activation of nuclear factor-kappaB, mitogen-activated protein kinase, protein kinase B/Akt and poly ADP-ribose polymerase, reactive oxygen species production, mitogen-activated protein kinase phosphatase-1 expression and mitochondrial depolarization were determined. We found that malvidin attenuated lipopolysaccharide-induced nuclear factor-kappaB, poly ADP-ribose polymerase and mitogen-activated protein kinase activation, reactive oxygen species production and mitochondrial depolarization, while upregulated the compensatory processes; mitogen-activated protein kinase phosphatase-1 expression and Akt activation.ConclusionsThese effects of malvidin may explain the previous findings and at least partially account for the positive effects of moderate red wine consumption on inflammation-mediated chronic maladies such as obesity, diabetes, hypertension and cardiovascular disease.
The Dbl family guanine-nucleotide exchange factors (GEFs) for Rho GTPases share the structural array of a Dbl homology (DH) domain in tandem with a Pleckstrin homology (PH) domain. For oncogenic Dbl, the DH domain is responsible for the GEF activity, and the DH-PH module constitutes the minimum structural unit required for cellular transformation. To understand the structure-function relationship of the DH domain, we have investigated the role of specific residues of the DH domain of Dbl in interaction with Rho GTPases and in Dbl-induced transformation. Alanine substitution mutagenesis identified a panel of DH mutants made in the ␣1, ␣6, and ␣9 regions and the PH junction site that suffer complete or partial loss of GEF activity toward Cdc42 and RhoA. Kinetic and binding analysis of these mutants revealed that although most displayed decreased k cat values in the GEF reaction, the substrate binding activities of T506A and R634A were significantly reduced. E502A, Q633A, and N673A/D674A, on the other hand, retained the binding capability to the Rho GTPases but lost the GEF catalytic activity. In general, the in vitro GEF activity of the DH mutants correlated with the in vivo Cdc42-and RhoA-activating potential, and the GEF catalytic efficiency mirrored the transforming activity in NIH 3T3 cells. Moreover, the N673A/D674A mutant exhibited a potent dominant-negative effect on serum-induced cell growth and caused retraction of actin structures. These studies identify important sites of the DH domain involved in binding or catalysis of Rho proteins and demonstrate that maintaining a threshold of GEF catalytic activity, in addition to the Rho GTPase binding activity, is essential for efficient transformation by oncogenic Dbl.
Abstract:The goal of the present study was to characterize the effects of RhoA at different stages of nerve growth factor (NGF)-induced neuronal differentiation in the PC12 model. This comparative analysis was prompted by previous studies that reported apparently opposite effects for Rho in different models of neuronal differentiation and regeneration. PC12 cells were transfected with activated V14RhoA or dominant negative N19RhoA under the control of either a constitutive or a steroid-regulated promoter. Upon exposure to NGF, V14RhoA cells continued to proliferate and did not extend neurites; however, they remained responsive to NGF, as indicated by the activation of extracellular signalregulated kinases. This inability to differentiate was reversed by C3 toxin and activation of cyclic AMP signaling, which inactivate RhoA. N19RhoA expression led to an increase in neurite initiation and branching. In contrast, when the RhoA mutants were expressed after NGF priming, only the rate of neurite extension was altered; V14RhoA clones had neurites approximately twice as long, whereas neurites of N19RhoA cells were ϳ50% shorter than those of appropriate controls. The effects of Rho in neurite regeneration mimicked those observed during the initial stages of morphogenesis; activation inhibited, whereas inactivation promoted, neurite outgrowth. Our results indicate that RhoA function changes at different stages of NGF-induced neuronal differentiation and neurite regeneration.
The dbl oncogene encodes a prototype member of the Rho GTPase guanine nucleotide exchange factor (GEF) family. Oncogenic activation of proto-Dbl occurs through truncation of the N-terminal 497 residues. The C-terminal half of proto-Dbl includes residues 498 to 680 and 710 to 815, which fold into the Dbl homology (DH) domain and the pleckstrin homology (PH) domain, respectively, both of which are essential for cell transformation via the Rho GEF activity or cytoskeletal targeting function. Here we have investigated the mechanism of the apparent negative regulation of proto-Dbl imposed by the N-terminal sequences. Deletion of the N-terminal 285 or C-terminal 100 residues of proto-Dbl did not significantly affect either its transforming activity or GEF activity, while removal of the N-terminal 348 amino acids resulted in a significant increase in both transformation and GEF potential. Proto-Dbl displayed a mostly perinuclear distribution pattern, similar to a polypeptide derived from its N-terminal sequences, whereas onco-Dbl colocalized with actin stress fibers, like the PH domain. Coexpression of the N-terminal 482 residues with onco-Dbl resulted in disruption of its cytoskeletal localization and led to inhibition of onco-Dbl transforming activity. The apparent interference with the DH and PH functions by the N-terminal sequences can be rationalized by the observation that the N-terminal 482 residues or a fragment containing residues 286 to 482 binds specifically to the PH domain, limiting the access of Rho GTPases to the catalytic DH domain and masking the intracellular targeting function of the PH domain. Taken together, our findings unveiled an autoinhibitory mode of regulation of proto-Dbl that is mediated by the intramolecular interaction between its N-terminal sequences and PH domain, directly impacting both the GEF function and intracellular distribution.The proto-Dbl protein is the prototype member of a large family of guanine nucleotide exchange factors (GEFs) for Rho GTPases (8,50). Oncogenic activation of proto-Dbl occurs by truncation of the amino-terminal 497 residues (41), resulting in constitutively active carboxyl-terminal sequences that include a Dbl homology (DH) domain in tandem with a pleckstrin homology (PH) domain, the conserved motifs of the Dbl family. Many members of this family, including Vav, Ect2, Tim, Ost, Dbs, Lbc, Lfc, Lsc, and Net, possess transformation or invasion ability, similar to onco-Dbl upon activation. In many cases, the DH-PH module represents the minimum structural unit that is required for cell transformation (8,50).A large body of evidence has helped establish that the biological functions of Dbl family members are intimately dependent upon their ability to interact with and activate Rho GTPases and that the cellular effects of Dbl-like proteins, including actin cytoskeletal reorganization, cell growth stimulation, and transformation, are likely the consequences of coordinated action of their immediate downstream substrates, the Rho family GTPases (8,47,50). The eviden...
The Rho family small GTPase Cdc42 transmits divergent intracellular signals through multiple effector proteins to elicit cellular responses such as cytoskeletal reorganization. Potential effectors of Cdc42 implicated in mediating its cytoskeletal effect in mammalian cells include PAK1, WASP, and IQGAP1. To investigate the determinants of Cdc42-effector specificity, we utilized recombinant Cdc42 mutants and chimeras made between Cdc42 and RhoA to map the regions of Cdc42 contributing to specific effector p21-binding domain (PBD) interaction. Site-directed mutants of the switch I domain and neighboring regions of Cdc42 demonstrated differential binding patterns toward the PBDs of PAK1, WASP, and IQGAP1, suggesting that switch I provides essential determinants for the effector binding, but recognition of each effector by Cdc42 involves a distinct mechanism. Differing from Rac1, the switch I domain and the surrounding region (amino acids 29 to 55) of Cdc42 appeared to be sufficient for specific binding to PAK1, whereas determinants outside the switch I domain, residues 157-191 and 84 -120 in particular, were necessary and sufficient to confer specificity to WASP and IQGAP1, respectively. In addition, IQGAP1, but not PAK1 nor WASP, required the unique "insert region," residues 122-134, of Cdc42 to achieve high affinity binding. Microinjection of the constitutively active Cdc42/ RhoA chimeras into serum-starved Swiss 3T3 cells showed that although preserving PAK1-and WASPbinding activity could retain the peripheral actin microspike (PAM)-inducing activity of Cdc42, interaction with PAK1 or WASP was not required for this activity. Moreover, IQGAP1-binding alone by Cdc42 was insufficient for PAM-induction. Thus, Cdc42 utilizes multiple distinct structural determinants to specify different effector recognition and to elicit PAM-inducing effect.
Summary Cardiovascular disease (CVD) is the leading cause of mortality in the Western world. The effort of research should aim at the primary prevention of CVD. Alongside statin therapy, which is maintained to be an effective method of CVD prevention, there are alternative methods such as vitamin B substitution therapy with folic acid (FA), and vitamins B12 and B6. B‐vitamins may inhibit atherogenesis by decreasing the plasma level of homocysteine (Hcy)—a suspected etiological factor for atherosclerosis—and by other mechanisms, primarily through their antioxidant properties. Although Hcy‐lowering vitamin trials have failed to demonstrate beneficial effects of B‐vitamins in the prevention of CVD, a meta‐analysis and stratification of a number of large vitamin trials have suggested their effectiveness in cardiovascular prevention (CVP) in some aspects. Furthermore, interpretation of the results from these large vitamin trials has been troubled by statin/aspirin therapy, which was applied along with the vitamin substitution, and FA fortification, both of which obscured the separate effects of vitamins in CVP. Recent research results have accentuated a new approach to vitamin therapy for CVP. Studies undertaken with the aim of primary prevention have shown that vitamin B substitution may be effective in the primary prevention of CVD and may also be an option in the secondary prevention of disease if statin therapy is accompanied by serious adverse effects. Further investigations are needed to determine the validity of vitamin substitution therapy before its introduction in the protocol of CVD prevention.
The dbl oncogene product (onco-Dbl) is the prototype member of a family of guanine nucleotide exchange factors (GEFs) for Rho GTPases. The Dbl homology (DH) domain of onco-Dbl is responsible for the GEF catalytic activity, and the DH domain, together with the immediately adjacent pleckstrin homology (PH) domain, constitutes the minimum module bearing transforming function. In the present study, we demonstrate that the onco-Dbl protein exists in oligomeric form in vitro and in cells. The oligomerization is mostly homophilic in nature and is mediated by the DH domain. Mutagenesis studies mapped the region involved in oligomerization to the conserved region 2 of the DH domain, which is located at the opposite side of the Rho GTPase interacting surface. Residue His556 of this region, in particular, is important for this activity, since the H556A mutant retained the GEF catalytic capability and the binding activity toward Cdc42 and RhoA in vitro but was deficient in oligomer formation. Consequently, the Rho GTPase activating potential of the H556A mutant was significantly reduced in cells. The focus-forming and anchorage-independent growth activities of onco-Dbl were completely abolished by the His556-to-Ala mutation, whereas the abilities to stimulate cell growth, activate Jun N-terminal kinase, and cause actin cytoskeletal changes were retained by the mutant. The ability of onco-Dbl to oligomerize allowed multiple Rho GTPases to be recruited to the same signaling complex, and such an ability is defective in the H556A mutant. Taken together, these results suggest that oligomerization of onco-Dbl through the DH domain is essential for cellular transformation by providing the means to generate a signaling complex that further augments and/or coordinates its Rho GTPase activating potential.The dbl oncogene product (onco-Dbl) was originally isolated from a diffuse B-cell lymphoma (16). Over the past decade, a large group of proteins has joined the Dbl family by virtue of their structural similarity with onco-Dbl in an approximately 300-amino-acid region consisting of a Dbl homology (DH) domain and a pleckstrin homology (PH) domain. Many members of this family, including Vav, Ect2, Tim, Ost, Dbs, Lbc, Lfc, Lsc, and Net, possess a transformation or invasion capability like onco-Dbl has. Other members include proteins identified as gene products of sequences that are rearranged in human diseases (Bcr or FGD1) or as proteins with other catalytic functions, such as the Sos or RasGRF Ras guanine nucleotide exchange factors (GEFs) (for reviews, see references 8 and 58).Onco-Dbl and the related yeast protein Cdc24 were among the first to be realized to function as Rho GTPase GEFs, i.e., to stimulate the replacement of bound GDP by GTP on specific members of the Rho family small GTPases (25, 62). Subsequent studies of individual Dbl-like molecules have found that Lbc, Lfc, and Lsc oncoproteins act as specific GEFs for Rho and cause cellular transformation through the Rho signaling pathway (19,57,64), the ost oncogene product sho...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.